Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by Mole101on Nov 21, 2020 3:52pm
175 Views
Post# 31947493

RE:RE:RE:Vaccine Discussion

RE:RE:RE:Vaccine DiscussionIf PMN  or any other companies are able  to come up with serology test that can do those things,not only the pharmaceutical companies would be interested, Goverments will be looking for them too.
There is a company that comes to mind and it’s involved in Serology test,...Sona Nanotech Inc. 
52 Week Range 0.0100 - 16.0500

It’s trading at 3.44 Canadian now as their products have encountered some road blocks and still under review by Goverments ... but you only have to look at that 52 week trading pattern, to see the great potencial that a successful Serology test may have on PMM .. any concerns about how to finance PMN 310 would go out the window ... I’m dreaming , but it’s posible and I’m hopeful 
<< Previous
Bullboard Posts
Next >>